Log in
FREE 15-Day Trial
Intelligent Investor
Intelligent Investor
  1. Home
  2. Research & Advice
  3. Research Tools
  4. Shares
  5. Immuron Limited (IMC)
  6. Company Announcements

Immuron Limited (ASX: IMC) - Announcements

- Current share price for IMC : $0.092

ASX company news and announcements for Immuron Limited (IMC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immuron Limited (IMC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immuron Limited (IMC), please use our Company Announcements tool to search across all ASX-listed companies.

Intelligent Investor free trial for buy hold sell stock recommendations

Latest company announcements for Immuron Limited (IMC)

Search all Announcements
Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg		 Gain/Loss
$21 Immuron`s Novel Influenza Product Advances to Human Trial 29 Aug 2011 9:01AM $0.066 $0.092 $0.092 risen by 39.39%
$21 Phase 2B NASH trial on track following meeting with FDA 22 Aug 2011 9:12AM $0.072 $0.092 $0.092 risen by 27.78%
$21 Notice of Non-Renounceable Rights Issue 17 Aug 2011 8:25AM $0.072 $0.092 $0.092 risen by 27.78%
$21 Travelan discovered to affect E.coli O104 outbreak in Europe 26 Jul 2011 10:29AM $0.072 $0.092 $0.092 risen by 27.78%
$21 HIV Program proceeds to Expanded Human Trial 21 Jul 2011 8:50AM $0.075 $0.092 $0.092 risen by 22.67%
$21 Shareholder Update 1 Jun 2011 9:10AM $0.064 $0.092 $0.092 risen by 43.75%
$21 Immuron Granted FDA pre-IND Meeting re Phase 2b Trial 19 Apr 2011 9:21AM $0.074 $0.092 $0.092 risen by 24.32%
$21 Immurons Influenza Program Shows Effectiveness in Trials 17 Mar 2011 9:10AM $0.069 $0.092 $0.092 risen by 33.33%
$21 Important Progress in HIV Prevention Project 8 Mar 2011 8:45AM $0.070 $0.092 $0.092 risen by 31.43%
$21 Immuron Granted Key Patent for Influenza Product 1 Mar 2011 10:18AM $0.075 $0.092 $0.092 risen by 22.67%
$21 Half Yearly Report and Accounts 1 Mar 2011 8:28AM $0.073 $0.092 $0.092 risen by 26.03%
$21 Australian Sales of Travelan expected to Increase 24 Feb 2011 9:57AM $0.075 $0.092 $0.092 risen by 22.67%
$21 Appointment of New Chief Executive Officer 17 Jan 2011 9:02AM $0.080 $0.092 $0.092 risen by 15%
$21 Preliminary Final Report 31 Aug 2010 2:51PM $0.078 $0.092 $0.092 risen by 17.95%
$21 Successful Results from NASH Clinical Trial 23 Aug 2010 8:29AM $0.100 $0.092 $0.092 fallen by 8%
$21 Immuron and Nycomed expand `Travelan` into other territories 11 Jun 2010 10:03AM $0.063 $0.092 $0.092 risen by 46.03%
$21 Collaboration with Nycomed on Influenza Product 21 May 2010 9:25AM $0.067 $0.092 $0.092 risen by 37.31%
$21 Strong Interest in Immuron NASH Product 17 May 2010 10:26AM $0.066 $0.092 $0.092 risen by 39.39%
$21 Nycomed Licenses Immuron`s Travelan Product 6 May 2010 8:43AM $0.065 $0.092 $0.092 risen by 41.54%
$21 Pre-clinical Trials for Influenza Prevention Product 4 May 2010 9:08AM $0.065 $0.092 $0.092 risen by 41.54%
$21 HIV Phase 2 trial completed. Final results expected mid year 19 Apr 2010 11:38AM $0.070 $0.092 $0.092 risen by 31.43%
$21 Shareholder Share Purchase Plan 19 Apr 2010 10:04AM $0.070 $0.092 $0.092 risen by 31.43%
$21 Phase II clinical trial for Metabolic Syndrome and NASH 29 Mar 2010 11:25AM $0.077 $0.092 $0.092 risen by 19.48%
$21 Half Yearly Report and Accounts 25 Feb 2010 5:56PM $0.080 $0.092 $0.092 risen by 15%
$21 Commencement of Phase 2 Clinical Trials - Metabolic Syndrome 16 Dec 2009 9:17AM $0.069 $0.092 $0.092 risen by 33.33%

576 - 600 of 612 results

Page 24 of 25

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.